[194 Pages Report] The Vaccine Contract Manufacturing Market size was estimated at USD 5.06 billion in 2023 and expected to reach USD 5.51 billion in 2024, at a CAGR 9.21% to reach USD 9.39 billion by 2030.
Vaccine contract manufacturing refers to outsourcing vaccine production processes to third-party organizations, known as contract manufacturing organizations (CMOs). These specialized companies possess the expertise, equipment, and facilities to produce vaccines at various stages, from initial development to full-scale production and packaging. Vaccine manufacturers partner with CMOs to expedite the development and manufacturing process, leverage specialized capabilities, manage costs, and ensure supply chain flexibility. The vaccine contract manufacturing market encompasses companies that provide a range of services on a contract basis for the pharmaceutical industry. This includes the production of vaccines at various stages, from early-stage development, such as preclinical trials, through to large-scale commercial production. It often involves upstream processes, such as antigen production, and downstream processes, including filling, finishing, and packaging. Vaccine contract manufacturers serve as critical partners for pharmaceutical firms, biotechnology companies, and research institutions that require additional capability or expertise in vaccine production. The vaccine contract manufacturing is growing due to increasing outbreaks of infectious diseases worldwide, growing governmental regulations and support for vaccine development, and rising vaccinations of newborns and children. However, the market faces certain challenges, such as the high cost associated with vaccines and the lack of proper storage infrastructure. On the other hand, technological advancements in mRNA vaccine technology and strategic partnerships and collaborations with governments and non-governmental organizations present potential opportunities for the vaccine contract manufacturing market.
The Americas region, with countries such as the United States and Canada, is characterized by advanced healthcare systems and a high degree of health awareness among the population. The United States stands as a prominent country in vaccine research. It has a vibrant ecosystem for biotech patents, with the government, industry, and academia actively investing in new vaccine technologies. In South America, increasing investment in biotechnology, government incentives for pharmaceutical manufacturing, growing public health expenditure, and the presence of bio-manufacturing facilities support the adoption of vaccine contract manufacturing. Europe has a mature vaccine contract manufacturing industry, benefiting from high-quality manufacturing standards and a stringent regulatory landscape. European Union (EU) countries actively engage in research and innovation, with a strong network of biotech firms and research institutes. The Middle East, while historically reliant on imported vaccines, is gradually developing its vaccine manufacturing capabilities, with nations including the United Arab Emirates and Saudi Arabia investing in local production facilities. Africa's market is heavily influenced by global health initiatives and partnerships focused on providing access to vaccines for all economic backgrounds. Asia Pacific represents a dynamic and rapidly growing vaccine contract manufacturing market due to its large population base, increasing healthcare expenditures, and growing awareness of the need for immunizations. Nations such as India and China are at the forefront, with a substantial number of manufacturing facilities contributing to the global vaccine supply. China has made significant investments in biotech and vaccine innovation, emphasizing the importance of technological upgrades. Japanese companies are investing in next-generation vaccines, including mRNA and DNA-based vaccines, while the government supports research through initiatives.
An attenuated vaccine uses a live version of the virus or bacteria that has been weakened, which cannot cause disease in people with healthy immune systems. This type of vaccine elicits a strong immune response and often requires fewer doses for long-term immunity. DNA vaccines employ a piece of genetic material from a pathogen to elicit an immune response. They direct the body's cells to produce an antigen that is native to the pathogen, prompting a specific immune response. DNA vaccines are still a relatively new technology and offer potential advantages in speed of development and stability, making them an interesting avenue for contract manufacturing. Inactivated vaccines contain viruses or bacteria that have been killed through physical or chemical processes. These vaccines do not pose a risk of causing the disease itself and are stable, making them suitable for a broad range of environments. Inactivated vaccines generally require adjuvants to enhance the immune response and may require multiple doses. Subunit vaccines include only the essential antigens of a virus or bacteria—rather than the whole pathogen. This approach minimizes the risk of side effects and is particularly useful when the pathogen cannot be cultivated in vitro or when the whole organism is unnecessary for immunization. Toxoid vaccines contain inactivated toxic compounds produced by bacteria that cause illness rather than the bacteria itself. These vaccines train the immune system to fight off the natural toxin, offering protection if the immunized individual ever encounters the actual pathogen. They are particularly useful for bacteria, such as Clostridium tetani, the cause of tetanus, where toxin production is the main cause of disease.
Downstream processing refers to the phase of vaccine manufacturing where the bulk product is refined and purified to meet regulatory standards and quality requirements. Key steps in downstream processing include the separation of cells and virus particles, removal of contaminants, and concentration and formulation of the vaccine. The need for downstream processing arises from the necessity to ensure that vaccines are safe, pure, and effective before they can be administered to the public. Upstream processing in vaccine manufacturing includes all steps necessary for the growth and initial harvest of the vaccine-producing biological system. This generally involves the culturing of cells or microorganisms that generate the vaccine antigen. The preference for cutting-edge upstream processing technologies stems from the fundamental need for consistent, scalable, and high-yield vaccine production.
The need for vaccine contract manufacturing in the human use segment is primarily driven by the global need to protect populations against infectious diseases. This segment encompasses the production of vaccines for a vast range of conditions, from annual influenza shots to immunizations against emerging public health threats, including COVID-19. Vaccine contract manufacturing for veterinary applications addresses the need for immunizations within animal populations, including both livestock and companion animals. The segment ensures the health of animals, which is crucial for food security and the prevention of zoonotic diseases that can transfer to humans.
The market dynamics represent an ever-changing landscape of the Vaccine Contract Manufacturing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Vaccine Contract Manufacturing Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Vaccine Contract Manufacturing Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Vaccine Contract Manufacturing Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Vaccine Contract Manufacturing Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Vaccine Contract Manufacturing Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Vaccine Contract Manufacturing Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Vaccine Contract Manufacturing Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Vaccine Contract Manufacturing Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Vaccine Contract Manufacturing Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Vaccine Contract Manufacturing Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Vaccine Contract Manufacturing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Vaccine Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
Vaxcyte, Inc. has reinforced its collaboration with Lonza Group AG, a contract development and manufacturing organization, to ensure the global launch preparedness of its line of pneumococcal conjugate vaccines (PCVs), namely VAX-24 and VAX-31, intended to protect both adult and pediatric demographics. In a significant deal, Vaxcyte will rely on Lonza's considerable manufacturing expertise to expedite the clinical progression of its vaccine candidates, beginning with VAX-24 in the US adult market. To meet the expected long-term worldwide demand, Lonza is dedicated to the establishment of a custom manufacturing suite at their state-of-the-art Ibex Dedicate Biopark in Visp, Switzerland, with the completion of its construction design and equipment installation slated for 2024. [Published On: 2023-10-16]
Oxford Acquires ABL Europe From Institut Mérieux For EUR 15 Mn
Oxford Biomedica plc, a vaccine contract development and manufacturing organization (CDMO), has purchased ABL Europe SAS from TSGH SAS, part of the Institut Mérieux Group, for a total consideration of EUR 15 million. The deal encompasses EUR 10 million of liquid assets infused into ABL Europe by Institut Mérieux before completion. The integration of ABL Europe into Oxford Biomedica's operations is expected to catapult the latter into the vanguard of global CDMOs within the cell and gene therapy field, enhancing its service offering and increasing its production capabilities, especially in process and analytical development, as well as early-stage manufacturing. [Published On: 2023-04-12]
Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
Samsung Biologics has confirmed its contract with Pfizer Inc. to manufacture COVID-19 vaccines for Moderna in a regulatory announcement, valued at 241 billion WON (USD 183 million), valid through 2029. As disclosed by the company, Samsung is directing substantial investment into the development of antibody-drug conjugates (ADCs), with manufacturing capabilities anticipated to come online within the year at their Incheon facility, fostering growth and diversification in their service offerings. [Published On: 2023-03-02]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Vaccine Contract Manufacturing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.
This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Attenuated Vaccine
- DNA Vaccines
- Inactivated Vaccine
- Subunit Vaccines
- Toxoid Vaccines
- Function
- Downstream
- Analytical & QC studies
- Fill & Finish Operations
- Packaging
- Upstream
- Bacterial Expression Systems
- Baculovirus or Insect Expression Systems
- Mammalian Expression Systems
- Yeast Expression Systems
- Downstream
- Application
- Human Use
- Veterinary
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Vaccine Contract Manufacturing Market, by Type
- Vaccine Contract Manufacturing Market, by Function
- Vaccine Contract Manufacturing Market, by Application
- Americas Vaccine Contract Manufacturing Market
- Asia-Pacific Vaccine Contract Manufacturing Market
- Europe, Middle East & Africa Vaccine Contract Manufacturing Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 468]
- List of Companies Mentioned [Total: 25]
Firstly, what is vaccine contract manufacturing? It is the process of outsourcing the manufacturing of vaccines to a third-party organization. Contract manufacturers specialize in the production and development of vaccines, both for commercial and clinical purposes. The increasing demand for vaccines has led to capacity expansion by contract manufacturers, with some companies even building new facilities to raise production levels.
The reasons behind the growing demand for vaccine contract manufacturing are numerous. Foremost, vaccines are currently the primary solution being sought against COVID-19 and other infectious diseases, leading to a surge in vaccine demand. Major pharmaceutical companies have also identified the need to focus on their core competencies and outsource vaccine production to contract manufacturers. Additionally, outsourcing vaccine production helps to cut costs, allowing companies to allocate their resources to research, development, and sales.
Besides increased capacity and cost savings, engaging a vaccine contract manufacturer offers many other benefits. These contract manufacturing facilities have state-of-the-art equipment, trained personnel, and strict quality control standards that minimize production risks and improve the final product quality. Contract manufacturers are also better equipped to navigate regulatory hurdles and ensure compliance with the regulatory authorities.
Vaccine contract manufacturing has also brought about a significant technological revolution in the vaccine industry. Contract manufacturers have the resources and expertise to optimize processes, develop new formulations and delivery technologies, and improve manufacturing standards. This has led to the development of novel vaccines and improved quality control processes, enabling faster and more efficient vaccine development.
In conclusion, vaccine contract manufacturing is essential to the increasing demand for vaccines globally. Contract manufacturers handle everything from research and development to commercial-scale production, allowing pharmaceutical companies to focus on their core competencies. Outsourcing vaccine production helps companies reduce costs, improve quality control, and minimize risks. Therefore, embracing and leveraging the technological advancements brought about by vaccine contract manufacturing is essential to address the ever-growing vaccine demand.
As the world battles the COVID-19 pandemic and other infectious diseases, it is becoming evident that vaccines are integral to saving lives and achieving herd immunity. Vaccine contract manufacturing offers a solution to the increased global demand for vaccines. Through quality control, technological revolution, and optimizing production processes, this service allows for increased production, reduced costs, and better quality. The pharmaceutical industry must embrace and leverage the benefits of vaccine contract manufacturing to meet the increasing vaccine demand.
- How big is the Vaccine Contract Manufacturing Market?
- What is the Vaccine Contract Manufacturing Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?